

January 30, 2024

BSE Limited

Floor 25, P. J. Towers Dalal Street, Fort Mumbai - 400 001

Scrip Code: **543271**

Bandra Kurla Complex Bandra (E), Mumbai - 400 051

Exchange Plaza

Trading Symbol: JUBLINGREA

National Stock Exchange of India Limited

Dear Sirs,

In terms of Regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") and SEBI Circular No. SEBI/HO/DDHS/DDHS_Div1/P/CIR/2022/000000103 (as amended), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2023 were approved by the Board of Directors of the Company at its meeting held today at 11:45 am and concluded at 2:45pm

Pursuant to applicable provisions of the Listing Regulations, we enclose the following:

- 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2023;
- 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter;
- 3. Declaration for unmodified Auditors' Report (Standalone and Consolidated).
- 4. The Board has declared an Interim Dividend of Rs.2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2023-24. Further, in terms of Regulation 42 of the Listing Regulations, the Board has fixed Friday, February 9, 2024 as 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend.

The Interim Dividend will be paid/dispatched on or before February 28, 2024.

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati Company Secretary Encl.: as above

A Jubilant Bhartia Company



Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 Uttar Pradesh, India CIN: L24299UP2019PLC122657

Walker Chandiok & Co LLP

Plot No. 19A, 2nd floor, Sector - 16A, Noida - 201 301 Uttar Pradesh, India

T+91 120 485 5999 F+91 120 485 5902

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 31 December 2023 and the year to date results for the period 01 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
- 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Madhu Sudan Malpani

Partner

Membership No. 517440

UDIN: 24517440BKGTYJ9533

Place: Noida

Date: 30 January 2024

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437
Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2023

(? in Lakhs)

-	Particulars		Quarter Ended		Nine Mon	Year Ended	
Sr. No.		31 December	30 September	31 December	31 December	31 March	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited) 2023	31 December (Unaudited) 2022	(Audited) 2023
		2023	2023	2022			
1	Revenue from operations						
	a) Sales/Income from operations	91074	99427	108484	292937	348186	45283
	b) Other operating income	596	882	567	2114	1670	3118
	Total revenue from operations	91670	100309	109051	295051	349856	45595
2	Other income	611	803	643	2575	2267	310
3	Total income (1+2)	92481	101112	109694	297626	352123	459060
4	Expenses						
	a) Cost of materials consumed	50113	47268	61752	155272	200318	254776
	b) Purchases of stock-in-trade	1437	799	2448	3571	7537	11343
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1220)	3260	(5505)	(3523)	(14534)	(12437
	d) Employee benefits expense	9005	9253	7286	26623	22962	30588
	e) Finance costs	1846	1590	1119	4964	2841	3824
	f) Depreciation and amortisation expense	3364	3329	2938	9862	9051	11974
	g) Other expenses:						
	- Power and fuel expense	11502	13565	18192	41305	56688	71988
	- Others	13433	14070	12007	40894	36147	50246
	Total expenses	89480	93134	100237	278969	321010	422302
5	Profit before tax (3-4)	3001	7978	9457	18657	31113	36758
6	Tax expense						
	- Current tax	525	1298	977	3219	5403	6405
	- Deferred tax charge	543	948	1686	2291	4236	5012
7	Net profit for the period/year (5-6)	1933	5732	6794	13147	21474	25341
8	Other comprehensive income (OCI)						
	i) a) items that will not be reclassified to profit or loss	(110)	(184)	(67)	(330)	(201)	(144
	b) Income tax relating to items that will not be reclassified to profit or loss	38	64	23	115	70	50
	ii) a) Items that will be reclassified to profit or loss					_	
	b) Income tax relating to items that will be reclassified to profit or loss	_				200	
9	Total comprehensive income for the period/year (7+8)	1861	5612	6750	12932	21343	25247
10	Earnings per share of ₹ 1 each (not annualised for the quarters/periods)						
	Basic (₹)	1.21	3.60	4,26	8.25	13.48	15 91
	Diluted (₹)	1.21	3.60	4.26	8 25	13 48	15.91
11	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593	1593	1593
		1553	2333	1333	223624	214260	214264
12	Reserves excluding revaluation reserves (other equity)					22.200	4,512.01
	See accompanying notes to the Standalone Unaudited Financial Results						





Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Nine Months Ended 31 December 2023

(₹ in Lakhs)

	Particulars		Quarter Ended		Nine Mon	Year Ended		
		31 December	30 September	31 December	31 December	31 December	31 March (Audited)	
r. No.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		
		2023	2023	2022	2023	2022	2023	
1	Segment revenue							
	a Speciality Chemicals	39238	45566	48883	129418	145522	19594	
	b Nutrition & Health Solutions	14273	20969	10131	52862	39407	5232	
	ç. Chemical Intermediates	43897	42993	53543	135479	182625	23025	
	Total	97408	109528	112557	317759	367554	47852	
	Less: Inter segment revenue	5738	9219	3506	22708	17698	2256	
	Total revenue from operations	91670	100309	109051	295051	349856	45595	
	a_ Speciality Chemicals	35289	36433	46136	108805	131866	17766	
	b. Nutrition & Health Solutions	14273	20969	10131	52862	39407	5232	
	c. Chemical Intermediates	42108	42907	52784	133384	178583	22596	
	Total	91670	100309	109051	295051	349856	45595	
2	Segment results (profit before tax and interest)							
	a Speciality Chemicals	3476	5639	5996	12716	16541	2026	
	b Nutrition & Health Solutions	977	2081	43	4725	2758	224	
	c. Chemical Intermediates	2052	3057	5406	9927	17119	2140	
	Total	6505	10777	11445	27368	36418	4390	
	Less: L. Interest (finance costs)	1846	1590	1119	4964	2841	382	
	ii Un-allocable expenditure (net of un-allocable income)	1658	1209	869	3747	2464	332	
	Profit before tax	3001	7978	9457	18657	31113	3675	
3	Segment assets							
	a Speciality Chemicals	228737	22969 9	219891	228737	219891	22012	
	b Nutrition & Health Solutions	37818	40264	36167	37818	36167	3495	
	c. Chemical Intermediates	119540	122527	120704	119540	120704	12680	
	d Unallocable corporate assets	33214	30511	21337	33214	21337	2395	
	Total segment assets	419309	423001	398099	419309	398099	40583	
4	Segment liabilities							
	a. Speciality Chemicals	26657	32802	41918	26657	41918	5214	
	b. Nutrition & Health Solutions	12627	11489	11342	12627	11342	1263	
	c. Chamical Intermediates	19017	44158	48731	49047	48731	4555	
	d. Unallocable corporate liabilities	105761	111449	80255	105761	80255	7964	
	Total segment liabilities	194092	199898	182246	194092	182246	18998	





Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Standalone)

			Quarter Ended		Nine Mon	Year Ended	
	Particulars		30 September	31 December	31 December	31 December	31 March
r. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2023	2023	2022	2023	2022	2023
1	Debt service coverage ratio (in times)#	4.45	8.11	12.07	6,75	15 14	13,7
	Definition: EBITDA/{finance costs + scheduled principol repayments (excluding prepayments) during the period for long-term debts)						
	(EBITDA: Profit before tox + depreciation and amortisation expense + finance costs)						
2	Interest service coverage ratio (in times)	4.45	8,11	12 07	6.75	15.14	13.7
	Definition: EBITDA/finance costs						
3	Bad debts to account receivable ratio (%)#	0.27%	0 05%	-	0.34%	0 04%	0.0
	Definition: Bad debts/average of opening and closing trade receivables						
	(Bod debts: Impairment balance as per statements of profit ond loss)						
4	Debtors turnover (in times)#	2.07	2.11	1.98	6 42	6 22	8 4
	Definition: Revenue from operations/overage of opening and closing trade receivables						
5	Inventory turnover (in times)#	0.57	0.53	0 68	1.73	2 38	3.0
	Definition: Cost of goods sold/overage of opening and closing inventories						
6	Operating margin (%)	4.40%	8.74%	9.11%	7.13⅓	9.06%	8.2
	Definition: Operating profit/revenue from operations						
b	[Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense -						
	other expenses}						
	(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finisned goods, stock-in-	0.00			1		
	trade and work-in-progress}				1		
7	Net profit margin (%)	2.09%	5.67%	6.19%	4.4236	6.10%	5.53
	Definition: Net profit/total income						
8	Net worth (In ₹ Lakhs)	225217	223103	215853	225217	215853	21585
	{Net worth: Equity share capital + other equity}						
9	Debt equity ratio (in times)	0.37	0.40	0.28	0.37	0.28	0.3
	Definition: Net debts/net worth						
	(Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cosh equivalents - other bank						
	balances)						
10	Current ratio (in times)	1.11	1.15	1.19	1,11	1,19	1,2
	Definition: Current assets/current liabilities						
11	Long term debt to working capital (in times)	2.19	1.52	0.60	2,19	0.60	1.0
	Definition: Long term debt/working capital						
	(Long term debt: Long term borrowings (gross of transaction costs)						
	{working capital: Current assets - current liabilities}					1	
12	Current liability ratio (in times)	0.68	0.69	0.76	0.68	0.76	0.4
	Definition: Current liabilities/total liabilities						
13	Total debts to total assets (in times)	0.20	0,21	0.16	0.20	0.16	0.:
	Definition: Total debts/total assets		,,,,,				
	[Total debts: Long term borrowings (gross of transaction costs) + short term borrowings]						

not annualised for the quarters/periods





Notes to standalone unaudited financial results (cont'd):

- 3. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4. The Board of Directors at its meeting held on 30 January 2024 has declared an interim dividend of ₹ 2.5 per share of ₹ 1 each amounting to ₹ 3982 lakhs.
- 5. During the quarter ended 31 December 2023, the Company has further invested an amount of ₹ 3400 lakhs in 0.50% optionally convertible debenture issued by its wholly owned subsidiary Jubilant Agro Sciences Limited.
- 6. During the quarter ended 31 December 2023, the Company has granted 787759 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company.
- 7. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30 January 2024. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com.

Place : Noida

Date: 30 January 2024

For Jubilant Ingrevia Limited

Deepak Jain
CEO & Managing Director





Walker Chandiok & Co LLP

Plot No. 19A, 2nd floor, Sector - 16A, Noida - 201 301 Uttar Pradesh, India

T +91 120 485 5999 F +91 120 485 5902

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- 1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 31 December 2023 and the consolidated year to date results for the period 01 April 2023 to 31 December 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, Issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

Charlered Accountants

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhu, 1 (1984), India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. The Statement also includes the Group's share of net profit after tax of ₹ 2.77 lakhs and ₹ 6.60 lakhs and total comprehensive income of ₹ 2.77 lakhs and ₹ 6.60 lakhs, for the quarter and nine months ended on 31 December 2023, respectively, as considered in the Statement, in respect of an associate, whose interim financial information has not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Madhu Sudan Malpani

Madhu Sudan

Partner

Membership No. 517440

UDIN: 24517440BKGTYK4607

Place: Noida

Date: 30 January 2024

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement:

S. No	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Agro Sciences Limited	Subsidiary
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate
9	AMP Energy Green Fifteen Private Limited	Associate



Regd. Office: Bhartlagram, Gajraula, Distt. Amroha-244 223 (U.P.) CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2023

(₹ in Lakhs)

	Particulars		Quarter Ended			ths Ended	Year Ended	
r. No.		31 December	30 September	31 December	31 December	31 December	31 March	
		(Unaudited)	(Unaudited)	(Unaudited) 2022	(Unaudited) 2023	(Unaudited) 2022	(Audited) 2023	
-		2023	2023	2022	2023	2022	2023	
1	Revenue from operations							
	a) Sales/Income from operations	96045	101110	115263	304021	361100	47404	
1	b) Other operating Income	595	884	568	2115	1671	322	
- 1	Total revenue from operations	96640	101994	115831	306136	362771	47726	
2	Other Income	878	852	700	2580	2437	333	
э	Total Income (1+2)	97518	102846	116531	308716	365208	48060	
4	Expenses							
	a) Cost of materials consumed	50113	47268	61724	155272	200290	25477	
1	h) Purchases of stock-in-trade	1814	1411	3291	5315	10708	1615	
- 1	c) Changes In Inventories of finished goods, stock-in-trade and work-in progress	(1067)	1848	(4026)	(4178)	(17629)	(1277	
- 1	d) Employee benefits expense	10112	10345	8239	29801	25746	3434	
- 1	g) Finance costs	1506	1252	669	3904	1588	215	
- 1	f) Depreciation and amortisation expense	3424	3391	3000	10045	9234	1221	
- 1	g) Other expenses:		****					
- 1	- Power and fuel expense	11104	13314	17893	40357	55881	7091	
	- Others	15007	16042	13580	46581	43266	5913	
	Total expenses	92013	94871	104370	287097	329084	43693	
5	Profit before share of profit/(loss) of an associate (3-4)	5505	7975	12161	21619	36124	4367	
1	H	3	12	(1)	7	(5)	4501	
- 1	Share of profit/(loss) of an associate	5508	7987	12160	21626	36119	4367	
	Profit before tax (5+6)	3306	/36/	12100	21020	30115	4307	
8	Tax expense	4400	4205	1013	4129	5873	702	
	- Current tax	1188	1265	1042				
_	- Deferred tax charge	464	973	1965	2133	4727	589	
	Net profit for the period/year (7-8)	3856	5749	9153	15364	25519	3075	
- 1	Other comprehensive income (OCI)							
- 1	i) a) Items that will not be reclassified to profit or loss	(132)	(130)	(116)	(229)	(233)	(16	
- 1	b) Income tax relating to items that will not be reclassified to profit or loss	40	59	23	105	70	2	
- 1	il) a) Items that will be reclassified to profit or loss	328	(58)	521	202	(48)	32	
	b) Income tax relating to items that will be reclassified to profit or loss	(159)	87	(329)	(58)	141	56	
11	Total comprehensive income for the period/year (9+10)	3933	5707	9252	15384	25449	3099	
	Net profit attributable to:							
	Owners of the Company	3856	5749	9153	15364	25519	3075	
	Non-controlling interests	2.0				•		
1	Other comprehensive income attributable to:							
	Owners of the Company	77	(42)	00	20	{70}	24	
	Non-controlling interests		•		11-1			
- 1	Total comprehensive income attributable to:							
	Owners of the Company	3933	5707	9252	15384	25449	3099	
	Non-controlling interests					-	_	
- 1	Earnings per share of ₹ 1 each (not annualised for the quarters/periods)							
	Basic (₹)	2 44	3 64	5,75	9.71	16 05	19 3	
	Dliuted (₹)	2.43	3 64	5.75	9 70	16 04	19.3	
	Paid-up equity share capital (face value per share ₹ 1)	1580	1580	1590	1580	1590	159	
	Reserves excluding revaluation reserves (other equity)			1	272599	263384	26503	
	See accompenying notes to the Consolidated Unaudited Financial Results							





Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Nine Months Ended 31 December 2023

(₹ in Lakhs)

			Quarter Ended		Nîne Mon	Year Ended	
	Backlandara	31 December	30 September	31 December	31 December	31 December	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2023	2023	2022	2023	2022	2023
1	Segment revenue						
	a. Speciality Chemicals	40427	47305	49500	131640	146691	198118
	b. Nutrition & Health Solutions	15122	16201	13206	51550	39594	55117
	c. Chemical Intermediates	46829	47707	56631	145654	194184	246602
	Total	102378	111213	119337	328844	380469	499837
	Loss : Inter segment revenue	5738	9219	3506	22708	17698	22568
	Total revenue from operations	96640	101994	115831	306136	362771	477269
	a. Speciality Chemicals	36478	38172	46753	111027	133035	179836
	b. Nutrition & Health Solutions	15122	16201	13206	51550	39594	55117
	c. Chemical Intermediates	45040	47621	55872	143559	190142	242316
:	Total	96540	101994	115831	306136	362771	477269
2	Segment results (profit before tax and interest)						
	a Speciality Chemicals	3486	4946	6999	12303	17715	21519
	b. Nutrition & Health Solutions	1409	1531	534	4296	3106	3264
	c. Chemical Intermediates	3774	3961	6199	12679	19379	24366
	Total	8669	10438	13732	29278	40200	49149
	Less: i. Interest (finance costs)	1506	1252	669	3904	1588	2158
	ii Un-allocable expenditure (net of un-allocable income)	1655	1199	903	3748	2493	3320
	Profit before tax	5508	7987	12160	21626	36119	43671
3	Segment assets]					
	a. Speciality Chemicals	254251	250887	226913	254251	226913	230381
	b. Nutrition & Health Solutions	49961	51286	46740	49961	46740	44553
	c Chemical Intermediates	133874	132798	131315	133874	131315	137256
	d Unallocable corporate assets	12667	12061	12310	12667	12310	13698
	Total segment assets	450753	447032	417278	450753	417278	425888
4	Segment liabilities						
	a. Speciality Chemicals	28194	33302	41178	28194	41178	52460
	b. Nutrition & Health Solutions	9778	8837	7804	9778	/804	8108
	c Chemical Intermediates	47281	38240	43624	47281	43624	39806
	d. Unallocable corporate liabilities	91321	96659	59698	91321	59698	58891
	Total segment liabilities	176574	177038	152304	176574	152304	159265





Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Consolidated)

			Quarter Ended		Nine Mon	Year Ended	
Sr. No.	Particulars	31 December	30 September	31 December	31 December	31 December	31 March
	1 0 110 1010	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2023	2023	2022	2023	2022	2023
1	Debt service coverage ratio (in times)#	6.93	10.09	23.64	9.11	29.56	26.90
	Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long- term debts)						
	{EBITDA: Profit before tox + depreciotion and amortisation expense + finance costs}						
2	Interest service coverage ratio (in times)	6.93	10.09	23.64	9.11	29.56	26.9
	Definition: EBITDA/finance costs						
3	Bad debts to account receivable ratio (%)#	0.27%	0.05%		D.33%	0.04%	0.09
	Definition: Bad debts/overage of opening ond closing trode receivables						
	{Bad debts: Impairment balance as per statements of profit and loss}						
4	Debtors turnover (in times)#	2.17	2.23	2.19	6.46	6.52	8.7
	Definition: Revenue from operations/average of opening and closing trade receivables						
5	Inventory turnover (in times)#	0.49	0.45	0.58	1.52	1.98	2.6
	Definition: Cast of gaods sold/average of opening and closing inventories						
6	Operating margin (%)	6.35%	8.21%	10.47%	7.49%	9.72%	8.90
	Definition: Operating profit/revenue from operations						
	{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and						
	amortisation expense - other expenses}						
	(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods,						
	stock-in-trade and work-in-progress}						
7	Net profit margin (%)	3.95%	5.59%	7 85%	4.98%	6.99%	6.40
	Definition: Net profit/total income						
8	Net worth (In ₹ Lakhs)	274179	269994	264974	274179	264974	266623
	{Net worth: Equity share capital + other equity}						
9	Debt equity ratio (in times)	0.23	0.26	0.13	0.23	0.13	0.1
	Definition: Net debts/net worth						
	{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents -						
	other bank balances}						
10	Current ratio (in times)	1.43	1.49	1.47	1.43	1.47	1.5
	Definition: Current assets/current liobilities						
11	Long term debt to working capital (in times)	0.59	0.51	-	0.59	•	0.2
	Definition: Long term debt/working capital						
	{Long term debt: Long term borrowings (gross of transaction costs)}						
	(working capital: Current assets - current liabilities)						
12	Current liability ratio (in times)	0.67	0.67	0.83	0.67	0.83	0.7
	Definition: Current liabilities/total liabilities						
13	Total debts to total assets (in times)	0.15	0.17	0.10	0.15	0,10	0.0
	Definition: Total debts/total ossets						
	{Total debts: Long term borrowings (gross of transaction costs + short term borrowings)						

not annualised for the quarters/periods





Notes to consolidated unaudited financial results (cont'd):

- 3. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)
- 4. The Board of Directors at its meeting held on 30 January 2024 has declared an interim dividend of ₹ 2.5 per share of ₹ 1 each amounting to ₹ 3982 lakhs.
- 5. During the quarter ended 31 December 2023, the Holding Company has granted 787759 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company.
- 6. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30 January 2024.

 These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited

Deepak Jain CEO & Managing Director

Place : Noida

Date: 30 January 2024







January 30, 2024

BSE Limited Floor 25, P. J. Towers Dalal Street, Fort

Mumbai - 400 001

Scrip Code: 543271

National Stock Exchange of India Limited

Exchange Plaza Bandra Kurla Complex Bandra (E), Mumbai - 400 051

Trading Symbol: JUBLINGREA

<u>Sub: Declaration pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular</u>

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/DDHS/DDHS_Div1/P/CIR/2022/0000000103 (as amended), we hereby state that the Statutory Auditors of the Company i.e. M/s Walker Chandiok & Co. LLP, Chartered Accountants (Firm Registration Number – 001076N/N500013) have issued an Auditor's Report with unmodified opinion on the unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter ended December 31, 2023.

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Prakash Chandra Bisht Chief Financial Officer



A Jubilant Bhartia Company

OUR VALUES

INSPIRE
CONFIDENCE

ALMAYS
STRETCH

Jubilant Ingrevia Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantingrevia.com Regd Office.
Bhartiagram, Gajraula
Distt. Amroha - 244-223
Uttar Pradesh, India
CIN: L24299UP2019PLC122657